ATI NURSING EDUCATION | PHARMACOLOGY
ATI PHARMACOLOGY PRACTICE
VERSION 3
Comprehensive practice examination aligned with the ATI Pharmacology Proctored Exam blueprint
for 2026-2027. Covers pharmacokinetics, pharmacodynamics, cardiovascular and renal medications,
respiratory and GI pharmacology, neurological and psychiatric medications, endocrine and
reproductive pharmacology, anti-infective agents, pain management, immunosuppressants,
toxicology, antidotes, and medication safety.
60 Questions | 8 Sections | Verified Correct Answers with Detailed Rationales
Questions and Answers with Rationale | Latest Version 2026/2027
, ATI PHARMACOLOGY PRACTICE VERSION 3
ATI NURSING EDUCATION | PHARMACOLOGY PROCTORED EXAM PREPARATION | 2026/2027 ALL QUESTIONS WITH
100% CORRECT ANSWERS
SECTION 1: PHARMACOKINETICS AND PHARMACODYNAMICS (Absorption, Distribution,
Metabolism, Excretion, Receptor Binding, Therapeutic Index, Half-Life, Drug Interactions)
Q1:
A nurse is administering a medication intravenously and explains to the patient that this route bypasses the
first-pass effect. Which of the following best describes the first-pass effect?
A. The rapid excretion of a drug by the kidneys before it reaches systemic circulation
B. The metabolism of a drug by the liver before it reaches systemic circulation **[CORRECT]**
C. The binding of a drug to plasma proteins reducing its active form
D. The absorption of a drug through the gastric mucosa into the bloodstream
Correct Answer: B
Rationale: The first-pass effect occurs when drugs absorbed from the GI tract are transported via the portal vein directly to
the liver, where significant metabolism occurs before the drug reaches systemic circulation. This can substantially reduce the
bioavailability of orally administered drugs. IV administration bypasses this effect entirely, which is why IV doses are often
lower than oral doses. Renal excretion and protein binding are unrelated to first-pass metabolism.
Q2:
A patient with liver cirrhosis is prescribed a medication that undergoes extensive hepatic metabolism. The nurse
anticipates which of the following adjustments to the medication regimen?
A. Increased dosage due to rapid drug clearance
B. Decreased dosage due to impaired metabolism and risk of toxicity **[CORRECT]**
C. No adjustment needed because hepatic metabolism is unaffected by cirrhosis
D. Switching to an oral formulation for better absorption
Correct Answer: B
Rationale: In liver cirrhosis, hepatic blood flow and functional hepatocyte mass are reduced, significantly impairing the
metabolism of drugs that undergo extensive first-pass hepatic metabolism. This leads to decreased clearance, prolonged
half-life, and increased risk of drug toxicity. The nurse should anticipate a decreased dosage to prevent adverse effects.
Increasing the dose would worsen toxicity, and oral bioavailability would actually increase due to reduced first-pass
metabolism.
Q3:
A nursing student asks about the therapeutic index of a medication. Which of the following statements best
describes a drug with a narrow therapeutic index?
A. The drug has a wide margin of safety between the effective dose and toxic dose
B. The drug requires frequent dosing due to rapid elimination
C. The difference between the effective dose and the toxic dose is small, increasing the risk of toxicity
**[CORRECT]**
D. The drug is highly effective at very low doses with minimal side effects
Correct Answer: C
Rationale: A narrow therapeutic index means there is a small difference between the minimum effective concentration and
the minimum toxic concentration of a drug. Examples include digoxin, warfarin, lithium, and phenytoin. These drugs require
careful therapeutic drug monitoring to ensure serum levels remain within the therapeutic window. A wide therapeutic index
indicates a large margin of safety, which is not the case here.
Q4:
A patient taking warfarin is started on phenobarbital for seizure management. The nurse should anticipate which
of the following outcomes?
A. Increased INR and increased risk of bleeding
B. Decreased INR and decreased effectiveness of warfarin **[CORRECT]**
C. No change in INR because the drugs act on different pathways
D. Increased risk of phenobarbital toxicity due to warfarin interaction
Correct Answer: B
ATI Pharmacology Practice V3 2026/2027 | Page 2
, Rationale: Phenobarbital is a potent CYP450 enzyme inducer that increases the hepatic metabolism of warfarin, leading to
decreased warfarin serum levels and a reduced INR. This decreases the anticoagulant effectiveness of warfarin, potentially
placing the patient at risk for thromboembolic events. The nurse should anticipate the need for an increased warfarin dose
and more frequent INR monitoring when phenobarbital is initiated.
Q5:
A nurse is caring for a patient who is highly protein-bound (98%) medication. The patient's albumin level is
critically low at 2.0 g/dL. Which of the following effects should the nurse anticipate?
A. Decreased free drug concentration leading to subtherapeutic effects
B. Increased free drug concentration leading to an increased risk of toxicity **[CORRECT]**
C. No change in drug effect because protein binding is unaffected by albumin levels
D. Increased metabolism of the drug due to increased free fraction availability
Correct Answer: B
Rationale: When albumin levels are low, fewer binding sites are available for highly protein-bound drugs. This leads to an
increase in the free (unbound) pharmacologically active fraction of the drug, which can result in toxicity at previously
therapeutic doses. This is particularly important for drugs like warfarin, phenytoin, and diazepam. The nurse should monitor
closely for signs of drug toxicity when albumin is low.
Q6:
A medication has a half-life of 4 hours. If the initial dose is 200 mg, approximately how much of the drug remains
in the body after 12 hours?
A. 25 mg **[CORRECT]**
B. 50 mg
C. 100 mg
D. 12.5 mg
Correct Answer: A
Rationale: The half-life is the time required for the plasma concentration of a drug to decrease by 50%. After 12 hours (which
is 3 half-lives for a drug with a 4-hour half-life), the remaining drug would be 200 mg x (0.5)^3 = 200 x 0.125 = 25 mg. After each
half-life, the remaining amount is halved: 200 mg at 0 hours, 100 mg at 4 hours, 50 mg at 8 hours, and 25 mg at 12 hours.
Q7:
A patient is receiving a continuous IV infusion of a medication that follows zero-order kinetics. Which of the
following best describes zero-order elimination?
A. A constant fraction of the drug is eliminated per unit time
B. A constant amount of the drug is eliminated per unit time regardless of concentration **[CORRECT]**
C. The drug is eliminated primarily by the kidneys at a fixed rate
D. The drug accumulates linearly until it reaches steady state
Correct Answer: B
Rationale: Zero-order kinetics means that a constant amount of drug is eliminated per unit time regardless of the plasma
concentration. This is in contrast to first-order kinetics, where a constant fraction (percentage) is eliminated per unit time.
Examples of drugs with zero-order kinetics at therapeutic concentrations include phenytoin, ethanol, and aspirin at high
doses. Most drugs follow first-order elimination.
Q8:
A nurse is reviewing medications that cross the blood-brain barrier (BBB). Which of the following characteristics
best describes a drug's ability to cross the BBB?
A. High molecular weight and high protein binding
B. Low lipid solubility and ionized state
C. High lipid solubility and low molecular weight **[CORRECT]**
D. High water solubility and large molecular size
Correct Answer: C
Rationale: The blood-brain barrier selectively limits the passage of substances into the CNS. Drugs that are highly
lipid-soluble, have low molecular weight, and are non-ionized (unionized) at physiological pH can most readily cross the BBB.
This is because the BBB is composed of tightly joined endothelial cells with lipid membranes. Highly protein-bound,
water-soluble, or large-molecule drugs have limited CNS penetration.
ATI Pharmacology Practice V3 2026/2027 | Page 3
ATI PHARMACOLOGY PRACTICE
VERSION 3
Comprehensive practice examination aligned with the ATI Pharmacology Proctored Exam blueprint
for 2026-2027. Covers pharmacokinetics, pharmacodynamics, cardiovascular and renal medications,
respiratory and GI pharmacology, neurological and psychiatric medications, endocrine and
reproductive pharmacology, anti-infective agents, pain management, immunosuppressants,
toxicology, antidotes, and medication safety.
60 Questions | 8 Sections | Verified Correct Answers with Detailed Rationales
Questions and Answers with Rationale | Latest Version 2026/2027
, ATI PHARMACOLOGY PRACTICE VERSION 3
ATI NURSING EDUCATION | PHARMACOLOGY PROCTORED EXAM PREPARATION | 2026/2027 ALL QUESTIONS WITH
100% CORRECT ANSWERS
SECTION 1: PHARMACOKINETICS AND PHARMACODYNAMICS (Absorption, Distribution,
Metabolism, Excretion, Receptor Binding, Therapeutic Index, Half-Life, Drug Interactions)
Q1:
A nurse is administering a medication intravenously and explains to the patient that this route bypasses the
first-pass effect. Which of the following best describes the first-pass effect?
A. The rapid excretion of a drug by the kidneys before it reaches systemic circulation
B. The metabolism of a drug by the liver before it reaches systemic circulation **[CORRECT]**
C. The binding of a drug to plasma proteins reducing its active form
D. The absorption of a drug through the gastric mucosa into the bloodstream
Correct Answer: B
Rationale: The first-pass effect occurs when drugs absorbed from the GI tract are transported via the portal vein directly to
the liver, where significant metabolism occurs before the drug reaches systemic circulation. This can substantially reduce the
bioavailability of orally administered drugs. IV administration bypasses this effect entirely, which is why IV doses are often
lower than oral doses. Renal excretion and protein binding are unrelated to first-pass metabolism.
Q2:
A patient with liver cirrhosis is prescribed a medication that undergoes extensive hepatic metabolism. The nurse
anticipates which of the following adjustments to the medication regimen?
A. Increased dosage due to rapid drug clearance
B. Decreased dosage due to impaired metabolism and risk of toxicity **[CORRECT]**
C. No adjustment needed because hepatic metabolism is unaffected by cirrhosis
D. Switching to an oral formulation for better absorption
Correct Answer: B
Rationale: In liver cirrhosis, hepatic blood flow and functional hepatocyte mass are reduced, significantly impairing the
metabolism of drugs that undergo extensive first-pass hepatic metabolism. This leads to decreased clearance, prolonged
half-life, and increased risk of drug toxicity. The nurse should anticipate a decreased dosage to prevent adverse effects.
Increasing the dose would worsen toxicity, and oral bioavailability would actually increase due to reduced first-pass
metabolism.
Q3:
A nursing student asks about the therapeutic index of a medication. Which of the following statements best
describes a drug with a narrow therapeutic index?
A. The drug has a wide margin of safety between the effective dose and toxic dose
B. The drug requires frequent dosing due to rapid elimination
C. The difference between the effective dose and the toxic dose is small, increasing the risk of toxicity
**[CORRECT]**
D. The drug is highly effective at very low doses with minimal side effects
Correct Answer: C
Rationale: A narrow therapeutic index means there is a small difference between the minimum effective concentration and
the minimum toxic concentration of a drug. Examples include digoxin, warfarin, lithium, and phenytoin. These drugs require
careful therapeutic drug monitoring to ensure serum levels remain within the therapeutic window. A wide therapeutic index
indicates a large margin of safety, which is not the case here.
Q4:
A patient taking warfarin is started on phenobarbital for seizure management. The nurse should anticipate which
of the following outcomes?
A. Increased INR and increased risk of bleeding
B. Decreased INR and decreased effectiveness of warfarin **[CORRECT]**
C. No change in INR because the drugs act on different pathways
D. Increased risk of phenobarbital toxicity due to warfarin interaction
Correct Answer: B
ATI Pharmacology Practice V3 2026/2027 | Page 2
, Rationale: Phenobarbital is a potent CYP450 enzyme inducer that increases the hepatic metabolism of warfarin, leading to
decreased warfarin serum levels and a reduced INR. This decreases the anticoagulant effectiveness of warfarin, potentially
placing the patient at risk for thromboembolic events. The nurse should anticipate the need for an increased warfarin dose
and more frequent INR monitoring when phenobarbital is initiated.
Q5:
A nurse is caring for a patient who is highly protein-bound (98%) medication. The patient's albumin level is
critically low at 2.0 g/dL. Which of the following effects should the nurse anticipate?
A. Decreased free drug concentration leading to subtherapeutic effects
B. Increased free drug concentration leading to an increased risk of toxicity **[CORRECT]**
C. No change in drug effect because protein binding is unaffected by albumin levels
D. Increased metabolism of the drug due to increased free fraction availability
Correct Answer: B
Rationale: When albumin levels are low, fewer binding sites are available for highly protein-bound drugs. This leads to an
increase in the free (unbound) pharmacologically active fraction of the drug, which can result in toxicity at previously
therapeutic doses. This is particularly important for drugs like warfarin, phenytoin, and diazepam. The nurse should monitor
closely for signs of drug toxicity when albumin is low.
Q6:
A medication has a half-life of 4 hours. If the initial dose is 200 mg, approximately how much of the drug remains
in the body after 12 hours?
A. 25 mg **[CORRECT]**
B. 50 mg
C. 100 mg
D. 12.5 mg
Correct Answer: A
Rationale: The half-life is the time required for the plasma concentration of a drug to decrease by 50%. After 12 hours (which
is 3 half-lives for a drug with a 4-hour half-life), the remaining drug would be 200 mg x (0.5)^3 = 200 x 0.125 = 25 mg. After each
half-life, the remaining amount is halved: 200 mg at 0 hours, 100 mg at 4 hours, 50 mg at 8 hours, and 25 mg at 12 hours.
Q7:
A patient is receiving a continuous IV infusion of a medication that follows zero-order kinetics. Which of the
following best describes zero-order elimination?
A. A constant fraction of the drug is eliminated per unit time
B. A constant amount of the drug is eliminated per unit time regardless of concentration **[CORRECT]**
C. The drug is eliminated primarily by the kidneys at a fixed rate
D. The drug accumulates linearly until it reaches steady state
Correct Answer: B
Rationale: Zero-order kinetics means that a constant amount of drug is eliminated per unit time regardless of the plasma
concentration. This is in contrast to first-order kinetics, where a constant fraction (percentage) is eliminated per unit time.
Examples of drugs with zero-order kinetics at therapeutic concentrations include phenytoin, ethanol, and aspirin at high
doses. Most drugs follow first-order elimination.
Q8:
A nurse is reviewing medications that cross the blood-brain barrier (BBB). Which of the following characteristics
best describes a drug's ability to cross the BBB?
A. High molecular weight and high protein binding
B. Low lipid solubility and ionized state
C. High lipid solubility and low molecular weight **[CORRECT]**
D. High water solubility and large molecular size
Correct Answer: C
Rationale: The blood-brain barrier selectively limits the passage of substances into the CNS. Drugs that are highly
lipid-soluble, have low molecular weight, and are non-ionized (unionized) at physiological pH can most readily cross the BBB.
This is because the BBB is composed of tightly joined endothelial cells with lipid membranes. Highly protein-bound,
water-soluble, or large-molecule drugs have limited CNS penetration.
ATI Pharmacology Practice V3 2026/2027 | Page 3
